American Biogenetic backs thrombosis risk test:
This article was originally published in Clinica
American Biogenetic Sciences has reached agreement with New Horizons Diagnostics to develop NHD's prototype Thrombus Precursor Protein (TpP) point of care test for soluble fibrin, a blood clot precursor. The in vitro test could be used for risk assessment of thrombosis and as a monitor during anti-coagulant therapies. ABS, based in Copiague, New York, also gains distribution rights to Columbia, Maryland-based NHD's other products.
You may also be interested in...
Celltrion has accelerated the development of its antiviral treatment for COVID-19 and aims to launch a rapid self-testing kit that could provide results within 15-20 minutes. The Korean firm also plans to develop a ‘super antibody’ to prepare for potential future pandemic situations.
Paracetamol, acetylcysteine and loperamide among list of OTC drugs deemed "essential" by Spain in the fight against coronavirus.
Mylan, in partnership with Indian firm Lupin, will be looking to rival Biogen and Sandoz by introducing an etanercept biosimilar in European markets following a positive opinion by the EMA’s CHMP on Mylan's application.